Halozyme Therapeutics, Inc. (NASDAQ:HALO) Stock Holdings Lifted by QS Investors LLC

QS Investors LLC lifted its stake in shares of Halozyme Therapeutics, Inc. (NASDAQ:HALO) by 1.7% in the 2nd quarter, according to the company in its most recent 13F filing with the SEC. The institutional investor owned 65,000 shares of the biopharmaceutical company’s stock after acquiring an additional 1,100 shares during the quarter. QS Investors LLC’s holdings in Halozyme Therapeutics were worth $2,952,000 as of its most recent filing with the SEC.

Other institutional investors and hedge funds also recently added to or reduced their stakes in the company. BlackRock Inc. lifted its position in shares of Halozyme Therapeutics by 3.4% during the 2nd quarter. BlackRock Inc. now owns 19,066,438 shares of the biopharmaceutical company’s stock worth $865,808,000 after purchasing an additional 628,960 shares during the last quarter. Vanguard Group Inc. raised its holdings in Halozyme Therapeutics by 2.9% in the 2nd quarter. Vanguard Group Inc. now owns 13,638,304 shares of the biopharmaceutical company’s stock valued at $619,315,000 after acquiring an additional 380,438 shares in the last quarter. FMR LLC raised its holdings in Halozyme Therapeutics by 5.0% in the 1st quarter. FMR LLC now owns 2,685,575 shares of the biopharmaceutical company’s stock valued at $43,238,000 after acquiring an additional 127,379 shares in the last quarter. Geode Capital Management LLC raised its holdings in Halozyme Therapeutics by 7.9% in the 2nd quarter. Geode Capital Management LLC now owns 2,446,622 shares of the biopharmaceutical company’s stock valued at $111,101,000 after acquiring an additional 179,364 shares in the last quarter. Finally, Price T Rowe Associates Inc. MD raised its holdings in Halozyme Therapeutics by 21.4% in the 1st quarter. Price T Rowe Associates Inc. MD now owns 1,513,095 shares of the biopharmaceutical company’s stock valued at $63,081,000 after acquiring an additional 266,361 shares in the last quarter. Institutional investors own 89.92% of the company’s stock.

HALO has been the subject of a number of recent research reports. TheStreet raised Halozyme Therapeutics from a “c+” rating to a “b” rating in a report on Monday, September 20th. Zacks Investment Research cut Halozyme Therapeutics from a “buy” rating to a “hold” rating and set a $45.00 target price for the company. in a report on Friday, July 16th. Two equities research analysts have rated the stock with a hold rating and six have assigned a buy rating to the company’s stock. According to MarketBeat.com, Halozyme Therapeutics currently has a consensus rating of “Buy” and a consensus target price of $51.67.

In other Halozyme Therapeutics news, Director Jean-Pierre Bizzari sold 35,000 shares of the stock in a transaction dated Wednesday, August 25th. The shares were sold at an average price of $41.01, for a total value of $1,435,350.00. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through the SEC website. Also, SVP Michael J. Labarre sold 29,450 shares of the stock in a transaction dated Friday, October 1st. The shares were sold at an average price of $39.93, for a total transaction of $1,175,938.50. The disclosure for this sale can be found here. In the last 90 days, insiders have sold 214,450 shares of company stock valued at $8,790,289. Corporate insiders own 2.60% of the company’s stock.

Shares of Halozyme Therapeutics stock opened at $36.90 on Thursday. The company has a market capitalization of $5.25 billion, a PE ratio of 23.65 and a beta of 1.43. Halozyme Therapeutics, Inc. has a 12 month low of $27.21 and a 12 month high of $56.40. The company has a current ratio of 8.75, a quick ratio of 8.24 and a debt-to-equity ratio of 6.56. The stock’s fifty day simple moving average is $40.60 and its 200 day simple moving average is $42.70.

Halozyme Therapeutics (NASDAQ:HALO) last released its quarterly earnings results on Monday, August 9th. The biopharmaceutical company reported $0.62 earnings per share (EPS) for the quarter, beating the Thomson Reuters’ consensus estimate of $0.43 by $0.19. Halozyme Therapeutics had a return on equity of 230.77% and a net margin of 55.45%. The firm had revenue of $136.50 million for the quarter, compared to the consensus estimate of $104.08 million. During the same quarter last year, the business posted $0.19 EPS. The company’s revenue for the quarter was up 147.3% on a year-over-year basis. Analysts predict that Halozyme Therapeutics, Inc. will post 1.82 EPS for the current fiscal year.

Halozyme Therapeutics Company Profile

Halozyme Therapeutics, Inc operates as a biopharma technology platform company in the United States, Switzerland, Ireland, Belgium, Japan, and internationally. The company's products are based on the ENHANZE drug delivery technology, a patented recombinant human hyaluronidase enzyme (rHuPH20) that enables the subcutaneous delivery of injectable biologics, such as monoclonal antibodies and other therapeutic molecules, as well as small molecules and fluids.

See Also: Death Cross

Institutional Ownership by Quarter for Halozyme Therapeutics (NASDAQ:HALO)

Receive News & Ratings for Halozyme Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Halozyme Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.